While immunohistochemical analyses and exomic sequencing are considered gold standards for determining IDH mutational status in gliomas [14,15], tissue heterogeneity, partial sampling of tissue specimens, and the presence of variable amounts of antigens constrain the utility of these methods in the reliable detection of IDH mutational status [16]. This evidence concerns the gene IDH2 and central nervous system cancer.